For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Omeros Corporation

USPTO Granted Patents = 97

CIPO Patents = 17

EPO Patents = 43

Trademarks = 22

Forward Citations = 802

Loading Chart...

Loading Chart...

112 inventors (with patents filed for the assignee):

Gregory A Demopulos (46 out of 65 patents)

Thomas Dudler (22 out of 24 patents)

Neil S Cutshall (21 out of 21 patents)

4. Jennifer Lynn Gage (18 out of 33 patents)

5. Hans-Wilhelm Schwaeble (15 out of 19 patents)

6. Jeffrey M Herz (15 out of 27 patents)

7. Munehisa Yabuki (12 out of 15 patents)

8. Clark E Tedford (12 out of 18 patents)

9. Larry W Tjoelker (11 out of 25 patents)

10. W Jason Cummings (10 out of 13 patents)

11. Thomas L Little, Jr (10 out of 27 patents)

12. Wayne Richard Gombotz (9 out of 20 patents)

13. Christi L Wood (9 out of 9 patents)

14. James Brian Parent (9 out of 14 patents)

15. George A Gaitanaris (8 out of 8 patents)

Core Competencies:

MASP-2 Inhibitors

Monoclonal Antibodies

Complement Activation

Chimeric Inhibitor Molecules

PDE7 Inhibitors

Fibrosis Inhibition

Angiogenesis Inhibition

Graft-Versus-Host Disease

Bioactive Peptide-Bearing Antibodies

Addiction Treatment

Intracameral Solutions

Optically Active PDE10 Inhibitor

97 patents: Sort by Forward Citations

1. 12351648 - Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome (2025-07-08),

2. 12195427 - MASP-2 inhibitors and methods of use (2025-01-14),

3. 12129290 - Monoclonal antibodies, compositions and methods for detecting complement factor D (2024-10-29),

4. 12110288 - MASP-2 inhibitors and methods of use (2024-10-08),

5. 12091468 - Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereof (2024-09-17),

6. 12030853 - MASP-2 inhibitors and methods of use (2024-07-09),

7. 12005117 - Methods for inhibiting fibrosis in a subject in need thereof (2024-06-11),

8. 11981749 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-05-14),

9. 11981748 - Methods for inhibiting angiogenesis in a subject in need thereof (2024-05-14),

10. 11945848 - Chimeric inhibitor molecules of complement activation (2024-04-02),

11. 11896621 - Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant (2024-02-13),

12. 11884742 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-01-30),

13. 11883493 - Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders (2024-01-30),

14. 11807641 - MASP-2 inhibitors and methods of use (2023-11-07),

15. 11661418 - MASP-2 inhibitors and methods of use (2023-05-30),

Omeros Corporation is a biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapeutics. With a focus on addressing unmet medical needs, Omeros has developed a diverse pipeline of product candidates targeting various indications, including inflammation, central nervous system disorders, and immune system disorders. The company is committed to improving patient outcomes through its research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

97 Patents

#20 in Seattle, WA

#63 in Washington

#3,765 in US

#7,790 in the World

Seattle, WA, United States of America

Omeros Corporation

Forward Citations = 802

112 inventors:

Gregory A Demopulos (46 out of 65 patents)

Thomas Dudler (22 out of 24 patents)

Neil S Cutshall (21 out of 21 patents)

4. Jennifer Lynn Gage (18 out of 33 patents)

5. Hans-Wilhelm Schwaeble (15 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…